Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Michael Scordo, MD, Gunjan L. Shah, MDMS, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Sean Devlin, PhD, Molly A. Maloy, MS, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Boglarka Gyurkocza, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD, Miguel Perales, MD, Sergio A. Giralt, MD, Brian C. Shaffer, MD

Blood (2016) 128 (22): 4621.

https://doi.org/10.1182/blood.V128.22.4621.4621

Published: 2016

Journal Articles

Selection of Unrelated Allogeneic Hematopoietic Cell Donors Based on KIR3DL1 Allotypes Is Feasible and Results in Improved Disease-Free Survival in Transplant Recipients with MDS and AML

Brian C. Shaffer, MD, Glenn Heller, PhD, Jean-Benoit Le Luduec, PhD, Jack Vahradian, Miguel Perales, MD, Sergio A. Giralt, MD, Roni Tamari, MD, Boglarka Gyurkocza, MD, Ann A. Jakubowski, MD PhD, E B Papadopoulos, MD, Jeanette E Boudreau, BSc, PhD, Nancy A. Kernan, MD, Katharine C. Hsu, MD PhD

Blood (2016) 128 (22): 990.

https://doi.org/10.1182/blood.V128.22.990.990

Published: 2016

Journal Articles

Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients

Carmen Lau, PharmD, Valkal Bhatt, PharmD, Parastoo B. Dahi, MD, Sean Devlin, PhD, Yeon Yoo, BS, Nelly G. Adel, PharmD, BCOP, BCPS, Chris Mazis, Miguel Perales, MD, Sergio A. Giralt, MD, Guenther Koehne, MD PhD, Doris M Ponce, MD, Genovefa A Papanicolaou, MD, Juliet N. Barker, MBBS (Hons)

Blood (2016) 128 (22): 2219.

https://doi.org/10.1182/blood.V128.22.2219.2219

Published: 2016

Journal Articles

A Novel Intermediate Intensity Conditioning Regimen Achieves High Rates of Long-Term Outpatient Progression-Free Survival Offsetting the Disadvantage of Early Post-Transplant Complications in Adult Cord Blood (CB) Transplant Recipients

Ioannis Politikos, MD, Sean Devlin, PhD, Yeon Yoo, BS, Christopher Mazis, BS, Molly A. Maloy, MS, Andromachi Scaradavou, MD, Parastoo B. Dahi, MD, Miguel Perales, MD, Sergio Giralt, MD, Doris M Ponce, MD, Juliet N. Barker, MBBS (Hons)

Blood (2016) 128 (22): 2193.

https://doi.org/10.1182/blood.V128.22.2193.2193

Published: 2016

Journal Articles

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Michael Scordo, MD, Gunjan Shah, MD M.S., Molly A. Maloy, MS, Sean Devlin, PhD, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Brian C. Shaffer, MD, Boglarka Gyurkocza, MD, Hugo R. Castro-Malaspina, MD, Roni Tamari, MD, Sergio A. Giralt, MD, Miguel Perales, MD

Blood (2016) 128 (22): 2194.

https://doi.org/10.1182/blood.V128.22.2194.2194

Published: 2016

Journal Articles

Real-World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Populationhematopoietic CELL Transplantation Among a Large US Commercially Insured Population

Neil C Josephson, MD, Phillip M. Garfin, MDPhD, Akshara Richhariya, PhD, Machaon Bonafede, McMorrow Donna, Qian Cai, Miguel Perales, MD

Blood (2016) 128 (22): 2368.

https://doi.org/10.1182/blood.V128.22.2368.2368

Published: 2016

Journal Articles

Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation

Kristen Beyer, PharmD, Anthony Proli, PharmD, Junting Zheng, Sean Devlin, PhD, Valkal Bhatt, PharmD, Andrew Lin, PharmD, Esperanza B. Papadopoulos, MD, Ann A. Jakubowski, MD PhD, Miguel Perales, MD, Sergio Giralt, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD

Blood (2016) 128 (22): 3392.

https://doi.org/10.1182/blood.V128.22.3392.3392

Published: 2016

Journal Articles

Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD)

Yi-Bin Chen, MD, Shuli Li, Sarah Konkel, Colleen Loiselle, Yvonne A. Efebera, MD MPH, Steven M. Devine, MD, Areej El-Jawahri, MD, Steven L. McAfee, MD, Robert J. Soiffer, MD, Jerome Ritz, MD, Corey S Cutler, MD MPH, Miguel Perales, MD

Blood (2015) 126 (23): 1930.

https://doi.org/10.1182/blood.V126.23.1930.1930

Published: 2015

Journal Articles

Quantitative Assessment of T Cell Repertoire Recovery after Double Unit Cord Blood Transplantation Demonstrates Early T Cell Diversity and Correlation Between CMV Reactivation and CD8 Clonal Domimance

Miguel Perales, MD, Ying Taur, MD, Ingrid Leiner, MS, Marissa N Lubin, BA, Boze Susac, BA, Eric G. Pamer, MD, Juliet N. Barker, MBBS(Hons), FRACP

Blood (2014) 124 (21): 1158.

https://doi.org/10.1182/blood.V124.21.1158.1158

Published: 2014

Journal Articles

Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience

Stephen S. Chung, MD, Jenna D Goldberg, MD, Esperanza B. Papadopoulos, MD, Ann A. Jakubowski, MD, PhD, Sean Devlin, PhD, Farid Boulad, MD, Miguel Perales, MD, Nancy A. Kernan, MD, Doris M Ponce, MD, Trudy N Small, MD, Guenther Koehne, MD, PhD, Juliet N Barker, MBBS, (Hons), FRACP, Richard J. O'Reilly, MD, Sergio A Giralt, MD, Marcel R.M. van den Brink, MD, PhD, James W. Young, MD, Hugo R Castro-Malaspina, MD

Blood (2012) 120 (21): 1996.

https://doi.org/10.1182/blood.V120.21.1996.1996

Published: 2012

Journal Articles

A Phase I Dose Escalation Trial of Donor T Cells Sensitized with Pentadecapeptides of the CMV-pp65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants.

Guenther Koehne, MD, PhD, Ekaterina Doubrovina, MD, PhD, Aisha Hasan, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Miguel Perales, MD, Ann Jakubowski, PhD, MD, Esperanza B Papadopoulos, MD, James W. Young, MD, Farid Boulad, MD, Trudy N Small, MD, Susan E Prockop, MD, Nancy A. Kernan, MD, Andromachi Scaradavou, MD, Genovefa Papanicolaou, Marcel van den Brink, MD, PhD, Richard J O'Reilly, MD

Blood (2009) 114 (22): 2262.

https://doi.org/10.1182/blood.V114.22.2262.2262

Published: 2009

Journal Articles

Response to Immunizations Following Allogeneic HCT with Adjuvant Rituximab Therapy.

Mary Pao, MD, PhD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Ann Jakubowski, MD, PhD, Nancy A. Kernan, MD, Miguel Perales, MD, Susan Prockop, MD, Ruth Ford, RN, James W. Young, MD, Richard J. O’Reilly, MD, Trudy N. Small, MD

Blood (2005) 106 (11): 3242.

https://doi.org/10.1182/blood.V106.11.3242.3242

Published: 2005

Journal Articles

Response to Hepatitis B Vaccination Following Allogeneic Hematopoietic Cell Transplantation (HCT).

Trudy N. Small, MD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Ann Jakubowski, MD, PhD, Nancy A. Kernan, MD, Miguel Perales, MD, Susan Prockop, MD, James W. Young, MD, Richard J. O’Reilly, MD, Dana Jaffe, MPH

Blood (2005) 106 (11): 83.

https://doi.org/10.1182/blood.V106.11.83.83

Published: 2005

Journal Articles

Vaccine Reponses Following Unmodified or T Cell Depleted Unrelated and Mismatched Related HCT.

Trudy N. Small, MD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, Nancy A. Kernan, MD, Ruth Ford, RN, Joanne Taylor, RN, Anne Casson, RN, PNP, Joann Torok-Castanza, RN, PNP, FNP, Bernadette Cuello, RN, NP, James W. Young, MD, Ann Jakubowksi, MD, PhD, Hugo Castro-Malaspina, MD, Miguel Perales, MD, Richard J. O’Reilly, MD

Blood (2004) 104 (11): 2226.

https://doi.org/10.1182/blood.V104.11.2226.2226

Published: 2004

NARROW

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Selection of Unrelated Allogeneic Hematopoietic Cell Donors Based on KIR3DL1 Allotypes Is Feasible and Results in Improved Disease-Free Survival in Transplant Recipients with MDS and AML

Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients

A Novel Intermediate Intensity Conditioning Regimen Achieves High Rates of Long-Term Outpatient Progression-Free Survival Offsetting the Disadvantage of Early Post-Transplant Complications in Adult Cord Blood (CB) Transplant Recipients

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Real-World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Populationhematopoietic CELL Transplantation Among a Large US Commercially Insured Population

Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation

Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD)

Quantitative Assessment of T Cell Repertoire Recovery after Double Unit Cord Blood Transplantation Demonstrates Early T Cell Diversity and Correlation Between CMV Reactivation and CD8 Clonal Domimance

Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience

A Phase I Dose Escalation Trial of Donor T Cells Sensitized with Pentadecapeptides of the CMV-pp65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants.

Response to Immunizations Following Allogeneic HCT with Adjuvant Rituximab Therapy.

Response to Hepatitis B Vaccination Following Allogeneic Hematopoietic Cell Transplantation (HCT).

Vaccine Reponses Following Unmodified or T Cell Depleted Unrelated and Mismatched Related HCT.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only